Insulet Co. (NASDAQ:PODD) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama reduced its position in Insulet Co. (NASDAQ:PODD) by 1.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,289 shares of the medical instruments supplier’s stock after selling 160 shares during the quarter. Retirement Systems of Alabama’s holdings in Insulet were worth $3,559,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PODD. Marshall Wace LLP bought a new stake in shares of Insulet in the 2nd quarter valued at approximately $99,978,000. Baillie Gifford & Co. increased its stake in Insulet by 30.8% during the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after purchasing an additional 443,783 shares during the last quarter. Mizuho Securities USA LLC raised its holdings in shares of Insulet by 5,928.1% during the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after purchasing an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares during the period. Finally, Westfield Capital Management Co. LP lifted its position in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after buying an additional 163,388 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Canaccord Genuity Group increased their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Raymond James raised their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Morgan Stanley upped their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $267.44.

Insulet Trading Up 0.0 %

Shares of NASDAQ:PODD opened at $256.56 on Friday. The company has a 50 day moving average of $253.81 and a 200-day moving average of $222.37. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a market cap of $18.00 billion, a P/E ratio of 43.93, a P/E/G ratio of 4.12 and a beta of 1.21. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.77.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.